{"id":"icp-488-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ICP-488 selectively inhibits epidermal growth factor receptor (EGFR) with activity against common activating mutations and some resistant variants. By blocking EGFR signaling, the drug suppresses downstream pathways that drive proliferation and survival in EGFR-mutant cancers, particularly non-small cell lung cancer.","oneSentence":"ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:13.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT07440537","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2026-03","conditions":"Cutaneous Lupus Erythematosus (CLE)","enrollment":105},{"nctId":"NCT06842199","phase":"PHASE3","title":"Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2025-03-20","conditions":"Plaque Psoriasis Patients","enrollment":383},{"nctId":"NCT06109818","phase":"PHASE2","title":"Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2024-01-04","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":129},{"nctId":"NCT05451199","phase":"PHASE1","title":"A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2022-07-29","conditions":"Psoriasis","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ICP-488 Tablets","genericName":"ICP-488 Tablets","companyName":"Beijing InnoCare Pharma Tech Co., Ltd.","companyId":"beijing-innocare-pharma-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation. Used for Non-small cell lung cancer with EGFR mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}